Meta facebook tracking pixel
Subscribe to these results:

Upcoming Workshops

For Breast Cancer

  1. Register
  2. Register
  3. Register
  4. Register
  5. Register
  6. Register

For Leukemia

  1. Register

For Lung Cancer

  1. Register

For Mantle Cell Lymphoma

  1. Register

For Ovarian Cancer

  1. Register

For Prostate Cancer

  1. Register

For Thyroid Cancer

For Uterine Cancer

  1. Register

Past workshops

For All Cancers

    1. Diverse Populations Participating in Decisions About Your Care With Your Health Care TeamPart II of How Health Care Disparities May Influence Your Cancer Treatment and Care
    2. Understanding Diagnostic Technologies and Biomarkers
    3. Clinical Trials: How They Transform the Treatment of Cancer
    4. Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care: With Tips and Strategies to Find the Best Cancer Treatment and Health Care Team for YouPart I of How Health Care Disparities May Influence Your Cancer Treatment and Care
    5. Understanding Diagnostic Technologies and Biomarkers
    6. Chemotherapy Treatment Side Effects: Prevention & Management
    7. Diverse Populations Participating in Decisions about Your Care with Your Health Care TeamPart II of How Health Care Disparities May Influence Your Cancer Treatment and Care
    8. Clinical Trials: How They Transform the Treatment of Cancer
    9. Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
    10. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    11. Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care: With Tips & Strategies to Find the Best Cancer Treatment & Health Care Team for YouPart I of How Health Care Disparities May Influence Your Cancer Treatment and Care
    12. CAR T-Cell Therapy: What's New
    13. Preventing, Managing & Treating Infection in Adults Living with Cancer
    14. What’s New in Precision Medicine
    15. How Health Care Disparities May Influence Your Cancer Treatment & Care
    16. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    17. Taking Your Pills on Schedule: Why It Is So Important in Managing Cancer
    18. Emerging Importance of Telemedicine/Telehealth Appointments in Communicating with Your Health Care Team
    19. Cancer and Flu Shots
    20. Treatment Adherence: Taking Your Pills on Schedule – Why It Is So Important
    21. What are Biosimilars? Understanding Their Role in Cancer Treatment: Current and Future Perspectives
    22. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    23. Participating in Decisions about Your CarePart IV of Life with Cancer: A Guide to Getting the Best Care
    24. Understanding the Costs of Care and Your Health Care CoveragePart II of Life with Cancer: A Guide to Getting the Best Care
    25. Taking Your Treatment on Schedule: Its Importance in Managing Cancer
    26. Care for Your Bones During & After Cancer Treatment: Tips to Improve Bone Health
    27. Participating in Decisions about Your CarePart V of Life with Cancer: A Guide to Getting the Best Care
    28. Medical Emergencies in Cancer Treatment

For Acute Lymphoblastic Leukemia

    1. Update on CAR T-Cell Therapies
    2. Follicular Lymphoma: Treatment Progress
    3. Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
    4. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    5. Chronic Lymphocytic Leukemia (CLL): Treatment Updates
    6. New Treatments for Childhood Acute Lymphocytic Leukemia (ALL)
    7. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    8. Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
    9. Progress in the Treatment of Myelodysplastic Syndromes (MDS)
    10. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    11. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    12. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    13. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    14. Transplantation as a Treatment Option for Blood Cancers
    15. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    16. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    17. Taking Your Blood Cancer Treatment on Schedule

For Acute Myeloid Leukemia

    1. Update on CAR T-Cell Therapies
    2. Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
    3. Acute Myelogenous Leukemia (AML): Current Treatment Perspectives
    4. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    5. Chronic Lymphocytic Leukemia (CLL): Treatment Updates
    6. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    7. Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
    8. Progress in the Treatment of Myelodysplastic Syndromes (MDS)
    9. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    10. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    11. Acute Myeloid Leukemia (AML): Treatment Updates
    12. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    13. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    14. Transplantation as a Treatment Option for Blood Cancers
    15. Update on the Treatment of Acute Myelogenous Leukemia (AML)
    16. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    17. Update on CAR T-Cell Therapies
    18. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    19. Taking Your Blood Cancer Treatment on Schedule

For Basal Cell Cancer

    1. Advanced Skin Cancer: New Perspectives in the Treatment of Advanced Basal Cell & Squamous Cell CancersPart I of Living with Advanced Skin Cancer and Melanoma
    2. New Perspectives in the Treatment of Advanced Skin Cancer: Advanced Basal Cell and Squamous Cell Cancers

For Bladder Cancer

    1. Bladder Cancer: Treatment Updates
    2. Bladder Cancer: Treatment UpdatePart I of Life with Bladder Cancer
    3. Bladder Cancer: Treatment UpdatesPart I of Life with Bladder Cancer
    4. Update on the Treatment of Bladder CancerPart I of Living with Bladder Cancer

For Bone Cancer

    1. Progress in the Treatment of Multiple MyelomaPart I of Living with Multiple Myeloma
    2. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches

For Brain Cancer

    1. Glioblastoma in Adults: Treatment Updates
    2. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – “Advancing Equitable Cancer Care Through Innovation"Part I of Highlights from the 2022 ASCO Annual Meeting
    3. Glioblastoma in Adults: Treatment Updates
    4. Update on Glioblastoma in Adults

For Breast Cancer

    1. Early Stage Breast Cancer: New Treatment Approaches
    2. Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
    3. Lobular Breast Cancer: Treatment Progress
    4. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    5. Updates in the Treatment of Estrogen Receptor (ER), Progesterone Receptor (PR) and HER2 Positive Breast Cancer from the 45th Annual San Antonio Breast Cancer SymposiumPart II of Living with Breast Cancer – Updates from the 45th Annual San Antonio Breast Cancer Symposium (SABCS)
    6. Updates from the 45th Annual San Antonio Breast Cancer Symposium on Triple Negative Breast Cancer
    7. Living with Breast Cancer – Updates from the 45th San Antonio Breast Cancer Symposium (SABCS)Part I of Living with Breast Cancer – Updates from the 45th Annual San Antonio Breast Cancer Symposium (SABCS)
    8. The Benefits of Clinical Trials for Triple Negative Breast Cancer
    9. Metastatic Triple Negative Breast CancerPart I of Living with Metastatic Triple Negative Breast Cancer
    10. Metastatic Breast Cancer: Treatment Updates
    11. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – “Advancing Equitable Cancer Care Through Innovation"Part I of Highlights from the 2022 ASCO Annual Meeting
    12. HER2-Positive Metastatic Breast Cancer: What’s New in Treatment & Quality-of-Life
    13. The Role of Radiation Therapy in the Treatment of Breast Cancer
    14. Metastatic Breast Cancer in African Americans: New Treatments
    15. Updates in the Treatment of Estrogen Receptor (ER) Positive, Progesterone Receptor (PR) Positive and HER2 Positive Breast Cancer from the San Antonio Breast Cancer Symposium (SABCS)Part II of Living with Breast Cancer, with Updates from the San Antonio Breast Cancer Symposium (SABCS)
    16. Updates from the 44th Annual San Antonio Breast Cancer Symposium (SABCS) on Triple Negative Breast Cancer (TNBC)
    17. The Latest Developments Reported at the 44th Annual San Antonio Breast Cancer Symposium (SABCS)Part I of Living with Breast Cancer, with Updates from the San Antonio Breast Cancer Symposium (SABCS)
    18. Triple Negative Breast Cancer and African American Women
    19. HER2-Positive Metastatic Breast Cancer: New Therapies
    20. Metastatic Breast Cancer: Treatment Updates
    21. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
    22. Updates on the Treatment of Estrogen Receptor (ER) Positive, Progesterone Receptor (PR) Positive & HER2 Positive Breast Cancer from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)Part II of Life with Breast Cancer - Updates from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)
    23. Triple Negative Breast Cancer and African American Women

For Cervical Cancer

    1. Cervical Cancer: Treatment Advances
    2. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – “Advancing Equitable Cancer Care Through Innovation"Part I of Highlights from the 2022 ASCO Annual Meeting
    3. Cervical Cancer: Treatment Advances

For Chronic Lymphocytic Leukemia

    1. Update on CAR T-Cell Therapies
    2. Follicular Lymphoma: Treatment Progress
    3. Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
    4. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    5. Chronic Lymphocytic Leukemia (CLL): Treatment Updates
    6. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    7. Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
    8. Progress in the Treatment of Myelodysplastic Syndromes (MDS)
    9. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    10. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    11. Chronic Lymphocytic Leukemia: Current Treatment PerspectivesPart II of Living with Chronic Lymphocytic Leukemia
    12. Chronic Lymphocytic Leukemia: What's NewPart I of Living with Chronic Lymphocytic Leukemia
    13. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    14. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    15. Transplantation as a Treatment Option for Blood Cancers
    16. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    17. Update on CAR T-Cell Therapies
    18. Current Perspectives on the Treatment of Chronic Lymphocytic Leukemia (CLL)Part II of Living with Chronic Lymphocytic Leukemia (CLL)
    19. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    20. Update on Chronic Lymphocytic Leukemia (CLL)Part I of Living with Chronic Lymphocytic Leukemia (CLL)
    21. Taking Your Blood Cancer Treatment on Schedule
    22. Life with CLL: Taking Charge of Your Treatment SchedulePart II of Life with Chronic Lymphocytic Leukemia (CLL)

For Chronic Myelogenous Leukemia

    1. Update on CAR T-Cell Therapies
    2. Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
    3. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    4. Chronic Lymphocytic Leukemia (CLL): Treatment Updates
    5. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    6. Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
    7. Progress in the Treatment of Myelodysplastic Syndromes (MDS)
    8. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    9. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    10. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    11. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    12. Transplantation as a Treatment Option for Blood Cancers
    13. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    14. Update on CAR T-Cell Therapies
    15. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    16. Taking Your Blood Cancer Treatment on Schedule

For Colorectal Cancer

    1. Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
    2. Advances in the Treatment of Colorectal Cancer
    3. Advances in the Treatment of Colorectal Cancer
    4. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
    5. Colorectal Cancer Treatment: Progress and Advances
    6. Colorectal Cancer Treatment: Progress & Advances
    7. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
    8. Advances in the Treatment of Colorectal Cancer

For Cutaneous T-Cell Lymphoma

    1. New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
    2. Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
    3. Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches
    4. Update on CAR T-Cell Therapies
    5. Follicular Lymphoma: Treatment Progress
    6. Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
    7. Non-Hodgkin Lymphoma: Current Treatment Progress
    8. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    9. Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
    10. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    11. Update On Marginal Zone Lymphoma (MZL)
    12. Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
    13. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    14. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    15. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    16. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    17. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    18. Transplantation as a Treatment Option for Blood Cancers
    19. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    20. Update on Diffuse Large B-Cell Lymphoma (DLBCL)
    21. Update on CAR T-Cell Therapies
    22. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    23. Taking Your Blood Cancer Treatment on Schedule

For Diffuse Large B-Cell Lymphoma

    1. New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
    2. Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
    3. Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches
    4. Update on CAR T-Cell Therapies
    5. Follicular Lymphoma: Treatment Progress
    6. Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
    7. Non-Hodgkin Lymphoma: Current Treatment Progress
    8. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    9. Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
    10. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    11. Update On Marginal Zone Lymphoma (MZL)
    12. Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
    13. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    14. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    15. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    16. Diffuse Large B-Cell Lymphoma (DLBCL) Updates
    17. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    18. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    19. Update on Diffuse Large B-Cell Lymphoma (DLBCL)
    20. Update on CAR T-Cell Therapies
    21. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    22. Taking Your Blood Cancer Treatment on Schedule

For Endometrial Cancer

    1. Progress in the Treatment of Endometrial Cancer
    2. Update on the Treatment of Endometrial Cancer

For Follicular Lymphoma

    1. New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
    2. Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
    3. Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches
    4. Update on CAR T-Cell Therapies
    5. Follicular Lymphoma: Treatment Progress
    6. Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
    7. Non-Hodgkin Lymphoma: Current Treatment Progress
    8. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    9. Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
    10. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    11. Update On Marginal Zone Lymphoma (MZL)
    12. Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
    13. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    14. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    15. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    16. Follicular Lymphoma: Treatment Progress
    17. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    18. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    19. Transplantation as a Treatment Option for Blood Cancers
    20. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    21. Update on Diffuse Large B-Cell Lymphoma (DLBCL)
    22. Update on CAR T-Cell Therapies
    23. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    24. Progress in the Treatment of Follicular Lymphoma
    25. Taking Your Blood Cancer Treatment on Schedule

For Gastric Cancer

    1. Gastric Cancer: Treatment Advances
    2. Gastric Cancer: Treatment Advances
    3. Gastric Cancer: Treatment Advances
    4. Gastric Cancer: Treatment Updates
    5. Advances in the Treatment of Gastric Cancer

For Gastrointestinal Stromal Tumors

    1. Gastric Cancer: Treatment Advances
    2. Gastric Cancer: Treatment Advances
    3. Gastric Cancer: Treatment Advances

For Glioblastoma

    1. Glioblastoma in Adults: Treatment Updates
    2. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – “Advancing Equitable Cancer Care Through Innovation"Part I of Highlights from the 2022 ASCO Annual Meeting
    3. Glioblastoma in Adults: Treatment Updates
    4. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
    5. Update on Glioblastoma in Adults

For Head and Neck Cancer

    1. Oral, Head and Neck Cancer: Treatment Updates
    2. Oral, Head & Neck Cancer: Treatment Update
    3. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
    4. Treatment Update in Oral and Head and Neck Cancer

For Hodgkin Lymphoma

    1. New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
    2. Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
    3. Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches
    4. Update on CAR T-Cell Therapies
    5. Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
    6. Non-Hodgkin Lymphoma: Current Treatment Progress
    7. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    8. Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
    9. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    10. Update On Marginal Zone Lymphoma (MZL)
    11. Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
    12. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    13. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    14. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    15. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    16. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    17. Transplantation as a Treatment Option for Blood Cancers
    18. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    19. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    20. Update on Diffuse Large B-Cell Lymphoma (DLBCL)
    21. Update on CAR T-Cell Therapies
    22. Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
    23. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    24. Taking Your Blood Cancer Treatment on Schedule

For Kidney Cancer

    1. Advances in the Treatment of Renal Cell Cancer
    2. Renal Cell Cancer: Treatment Advances
    3. Advances in the Treatment of Renal Cell Cancer

For Leukemia

    1. Update on CAR T-Cell Therapies
    2. Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
    3. Acute Myelogenous Leukemia (AML): Current Treatment Perspectives
    4. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    5. Chronic Lymphocytic Leukemia (CLL): Treatment Updates
    6. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
    7. New Treatments for Childhood Acute Lymphocytic Leukemia (ALL)
    8. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    9. Adults Living with Acute Lymphocytic Leukemia (ALL): Treatment Updates
    10. Progress in the Treatment of Myelodysplastic Syndromes (MDS)
    11. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    12. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    13. Acute Myeloid Leukemia (AML): Treatment Updates
    14. Chronic Lymphocytic Leukemia: Current Treatment PerspectivesPart II of Living with Chronic Lymphocytic Leukemia
    15. Chronic Lymphocytic Leukemia: What's NewPart I of Living with Chronic Lymphocytic Leukemia
    16. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    17. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    18. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
    19. Transplantation as a Treatment Option for Blood Cancers
    20. Progress in the Treatment of Myelofibrosis
    21. Update on the Treatment of Acute Myelogenous Leukemia (AML)
    22. Update on CAR T-Cell Therapies
    23. Current Perspectives on the Treatment of Chronic Lymphocytic Leukemia (CLL)Part II of Living with Chronic Lymphocytic Leukemia (CLL)
    24. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    25. Update on Chronic Lymphocytic Leukemia (CLL)Part I of Living with Chronic Lymphocytic Leukemia (CLL)
    26. Taking Your Blood Cancer Treatment on Schedule
    27. Life with CLL: Taking Charge of Your Treatment SchedulePart II of Life with Chronic Lymphocytic Leukemia (CLL)

For Liver Cancer

    1. Liver Cancer: Treatment Update
    2. Liver Cancer: Treatment Updates
    3. Liver Cancer: Treatment Updates
    4. Liver Cancer: Treatment Updates

For Lung Cancer

    1. Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
    2. Diverse Populations Living with Non-Small Cell Lung Cancer
    3. Update on Small Cell Lung CancerPart I of Living with Small Cell Lung Cancer
    4. Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
    5. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    6. Non-Small Cell Lung Cancer: What's NewPart I of Living with Non-Small Cell Lung Cancer
    7. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
    8. Genomic Testing and Current Trends in the Treatment of Non-Small Cell Lung CancerPart III of Living with Non-Small Cell Lung Cancer
    9. Small Cell Lung Cancer: Treatment UpdatePart I of Living with Small Cell Lung Cancer
    10. Non-Small Cell Lung Cancer: Treatment AdvancesPart I of Living with Non-Small Cell Lung Cancer
    11. Non-Small Cell Lung Cancer: What’s NewPart I of Living with Non-Small Cell Lung Cancer
    12. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
    13. Diverse Populations Living with Non-Small Cell Lung Cancer
    14. Advances in the Treatment of Lung CancerPart I of Living with Lung Cancer
    15. Update on Small Cell Lung Cancer Treatments
    16. For Caregivers: Practical Tips for Coping with Your Loved One’s Lung CancerPart II of Living with Lung Cancer
    17. For Caregivers: Practical Tips for Coping with Your Loved One’s Lung Cancer During the HolidaysPart II of Life with Lung Cancer

For Lymphoma

    1. New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
    2. Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
    3. Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches
    4. Update on CAR T-Cell Therapies
    5. Follicular Lymphoma: Treatment Progress
    6. Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
    7. Non-Hodgkin Lymphoma: Current Treatment Progress
    8. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    9. Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
    10. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    11. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
    12. Update On Marginal Zone Lymphoma (MZL)
    13. Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
    14. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    15. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    16. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    17. Mantle Cell Lymphoma: Treatment UpdatePart I of Living with Mantle Cell Lymphoma (MCL)
    18. Follicular Lymphoma: Treatment Progress
    19. Diffuse Large B-Cell Lymphoma (DLBCL) Updates
    20. Marginal Zone Lymphoma (MZL): Treatment Updates
    21. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    22. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    23. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
    24. Transplantation as a Treatment Option for Blood Cancers
    25. Update on Marginal Zone Lymphoma (MZL)
    26. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    27. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    28. Update on Diffuse Large B-Cell Lymphoma (DLBCL)
    29. Update on CAR T-Cell Therapies
    30. Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
    31. Treatment Update on Mantle Cell Lymphoma (MCL)Part I of Living with Mantle Cell Lymphoma
    32. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    33. Progress in the Treatment of Follicular Lymphoma
    34. Taking Your Blood Cancer Treatment on Schedule

For Mantle Cell Lymphoma

    1. New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
    2. Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
    3. Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches
    4. Update on CAR T-Cell Therapies
    5. Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
    6. Non-Hodgkin Lymphoma: Current Treatment Progress
    7. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    8. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    9. Update On Marginal Zone Lymphoma (MZL)
    10. Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
    11. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    12. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    13. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    14. Mantle Cell Lymphoma: Treatment UpdatePart I of Living with Mantle Cell Lymphoma (MCL)
    15. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    16. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    17. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    18. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    19. Update on Diffuse Large B-Cell Lymphoma (DLBCL)
    20. Update on CAR T-Cell Therapies
    21. Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
    22. Treatment Update on Mantle Cell Lymphoma (MCL)Part I of Living with Mantle Cell Lymphoma
    23. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    24. Taking Your Blood Cancer Treatment on Schedule

For Marginal Zone Lymphoma

    1. New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
    2. Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
    3. Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches
    4. Update on CAR T-Cell Therapies
    5. Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
    6. Non-Hodgkin Lymphoma: Current Treatment Progress
    7. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    8. Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
    9. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    10. Update On Marginal Zone Lymphoma (MZL)
    11. Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
    12. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    13. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    14. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    15. Marginal Zone Lymphoma (MZL): Treatment Updates
    16. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    17. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    18. Update on Marginal Zone Lymphoma (MZL)
    19. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    20. Update on Diffuse Large B-Cell Lymphoma (DLBCL)
    21. Update on CAR T-Cell Therapies
    22. Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
    23. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    24. Taking Your Blood Cancer Treatment on Schedule

For Melanoma

    1. Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
    2. Emerging Treatments for Metastatic MelanomaPart II of Living with Advanced Skin Cancer and Melanoma
    3. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    4. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
    5. People of Color Living with Skin Cancer
    6. Emerging Treatments for Metastatic MelanomaPart II of Living with Advanced Skin Cancer and Melanoma
    7. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
    8. Emerging Treatments for Metastatic MelanomaPart II of Living with Advanced Skin Cancer and Melanoma
    9. New Perspectives in the Treatment of Advanced Skin Cancer: Advanced Basal Cell and Squamous Cell CancersPart I of Living with Advanced Skin Cancer and Melanoma

For Merkel Cell Carcinoma

    1. Emerging Treatments for Metastatic MelanomaPart II of Living with Advanced Skin Cancer and Melanoma

For Mesothelioma

    1. Mesothelioma: Innovative Treatment Options
    2. Mesothelioma: Innovative Treatment Options
    3. Mesothelioma: Innovative Treatment Options

For Metastatic Breast Cancer

    1. Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
    2. Lobular Breast Cancer: Treatment Progress
    3. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    4. Updates in the Treatment of Estrogen Receptor (ER), Progesterone Receptor (PR) and HER2 Positive Breast Cancer from the 45th Annual San Antonio Breast Cancer SymposiumPart II of Living with Breast Cancer – Updates from the 45th Annual San Antonio Breast Cancer Symposium (SABCS)
    5. Updates from the 45th Annual San Antonio Breast Cancer Symposium on Triple Negative Breast Cancer
    6. Living with Breast Cancer – Updates from the 45th San Antonio Breast Cancer Symposium (SABCS)Part I of Living with Breast Cancer – Updates from the 45th Annual San Antonio Breast Cancer Symposium (SABCS)
    7. Metastatic Triple Negative Breast CancerPart I of Living with Metastatic Triple Negative Breast Cancer
    8. Metastatic Breast Cancer: Treatment Updates
    9. HER2-Positive Metastatic Breast Cancer: What’s New in Treatment & Quality-of-Life
    10. The Role of Radiation Therapy in the Treatment of Breast Cancer
    11. Metastatic Breast Cancer in African Americans: New Treatments
    12. Updates in the Treatment of Estrogen Receptor (ER) Positive, Progesterone Receptor (PR) Positive and HER2 Positive Breast Cancer from the San Antonio Breast Cancer Symposium (SABCS)Part II of Living with Breast Cancer, with Updates from the San Antonio Breast Cancer Symposium (SABCS)
    13. Updates from the 44th Annual San Antonio Breast Cancer Symposium (SABCS) on Triple Negative Breast Cancer (TNBC)
    14. The Latest Developments Reported at the 44th Annual San Antonio Breast Cancer Symposium (SABCS)Part I of Living with Breast Cancer, with Updates from the San Antonio Breast Cancer Symposium (SABCS)
    15. HER2-Positive Metastatic Breast Cancer: New Therapies
    16. Metastatic Breast Cancer: Treatment Updates
    17. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
    18. Updates on the Treatment of Estrogen Receptor (ER) Positive, Progesterone Receptor (PR) Positive & HER2 Positive Breast Cancer from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)Part II of Life with Breast Cancer - Updates from the 43rd Annual San Antonio Breast Cancer Symposium (SABCS)
    19. Triple Negative Breast Cancer and African American Women

For Multiple Myeloma

    1. Progress in the Treatment of Multiple MyelomaPart I of Living with Multiple Myeloma
    2. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    3. Progress in the Treatment of Multiple Myeloma
    4. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    5. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    6. Coping with the Stresses of Caregiving When Your Loved One Has Multiple MyelomaPart II of Living with Multiple Myeloma
    7. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    8. Progress in the Treatment of Multiple MyelomaPart I of Living with Multiple Myeloma
    9. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    10. Transplantation as a Treatment Option for Blood Cancers
    11. Update on CAR T-Cell Therapies
    12. Progress in the Treatment of Multiple Myeloma
    13. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    14. Taking Your Blood Cancer Treatment on Schedule

For Myelodysplastic Syndromes

    1. Progress in the Treatment of Myelodysplastic Syndromes (MDS)
    2. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    3. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    4. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    5. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
    6. Transplantation as a Treatment Option for Blood Cancers
    7. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    8. Update on CAR T-Cell Therapies
    9. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    10. Taking Your Blood Cancer Treatment on Schedule

For Myelofibrosis

    1. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    2. Transplantation as a Treatment Option for Blood Cancers
    3. Progress in the Treatment of Myelofibrosis
    4. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    5. Update on CAR T-Cell Therapies
    6. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    7. Taking Your Blood Cancer Treatment on Schedule

For Myeloproliferative Neoplasms

    1. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    2. Chronic Lymphocytic Leukemia (CLL): Treatment Updates
    3. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    4. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    5. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    6. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.
    7. Transplantation as a Treatment Option for Blood Cancers
    8. Progress in the Treatment of Myelofibrosis
    9. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    10. Update on CAR T-Cell Therapies
    11. Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
    12. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    13. Taking Your Blood Cancer Treatment on Schedule

For Non-Hodgkin Lymphoma

    1. New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
    2. Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
    3. Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches
    4. Update on CAR T-Cell Therapies
    5. Follicular Lymphoma: Treatment Progress
    6. Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
    7. Non-Hodgkin Lymphoma: Current Treatment Progress
    8. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    9. Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
    10. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    11. Update On Marginal Zone Lymphoma (MZL)
    12. Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
    13. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    14. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    15. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    16. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    17. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    18. Transplantation as a Treatment Option for Blood Cancers
    19. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    20. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    21. Update on CAR T-Cell Therapies
    22. Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
    23. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    24. Progress in the Treatment of Follicular Lymphoma
    25. Taking Your Blood Cancer Treatment on Schedule

For Ovarian Cancer

    1. Ovarian Cancer: Treatment Updates
    2. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting – “Advancing Equitable Cancer Care Through Innovation"Part I of Highlights from the 2022 ASCO Annual Meeting
    3. Ovarian Cancer: Treatment Updates
    4. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart I of Equity. Every Patient. Every Day. Everywhere.
    5. Medical Update on Ovarian Cancer

For Pancreatic Cancer

    1. Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
    2. Highlights from the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - "Advancing Equitable Cancer Care Through Innovation"Part II of Highlights from the 2022 ASCO Annual Meeting
    3. Highlights from the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingPart II of Equity. Every Patient. Every Day. Everywhere.

For Peripheral T-Cell Lymphoma

    1. New Perspectives in the Treatment of Peripheral T-Cell Lymphoma (PTCL)
    2. Highlights from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – “Partnering With Patients: The Cornerstone of Cancer Care and Research”Part II of Highlights from the 2023 American Society of Clinical Oncology Meeting
    3. Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches
    4. Update on CAR T-Cell Therapies
    5. Follicular Lymphoma: Treatment Progress
    6. Managing the Side Effects of ImmunotherapyPart II of New Trends in Immunotherapy
    7. Non-Hodgkin Lymphoma: Current Treatment Progress
    8. Understanding the Role of Immunotherapy in Treating CancerPart I of New Trends in Immunotherapy
    9. Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates
    10. Update from the 2022 American Society of Hematology (ASH) Annual Meeting
    11. Update On Marginal Zone Lymphoma (MZL)
    12. Waldenstrom’s Macroglobulinemia (WM): Treatment Progress
    13. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    14. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    15. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    16. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    17. Update from the 2021 American Society of Hematology (ASH) Annual Meeting
    18. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL)
    19. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    20. Update on Diffuse Large B-Cell Lymphoma (DLBCL)
    21. Update on CAR T-Cell Therapies
    22. Progress in the Treatment of Waldenstrom’s Macroglobulinemia (WM)
    23. Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of Taking Your Treatment on Schedule
    24. Taking Your Blood Cancer Treatment on Schedule

For Polycythemia Vera

    1. What’s New in Diagnostic Technologies for People Living with Blood CancersPart II of The Role of Diagnostic Technologies in Transforming the Treatment of People Living with Cancer
    2. Transplantation as a Treatment Option for Blood Cancers
    3. Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow Transplantation: New Treatment Approaches
    4. Update on CAR T-Cell Therapies